Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/urine-mesna-excretion-after-intravenous-and-oral-dosing-in-ifosfamide-2f1tFuOmQ1
References (9)
-
M. Goren, L. Anthony, K. Hande, D. Johnson, W. Brade, M. Frazier, D. Bush, J. Li (1998)
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 2
-
M. Goren, J. Houle, D. Bush, J. Li, C. Newman, W. Brade (1998)
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 10
-
N. Brock, J. Pohl, J. Stekar, W. Scheef (1982)
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).European journal of cancer & clinical oncology, 18 12
-
J. Mace, M. Keohan, Heinz Bernardy, K. Junge, G. Niebch, P. Romeis, A. Thoma, T. Wagner, U. Mueller, G. Demetri, L. Baker (2003)
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 16 Pt 1
-
N. Brock, J. Pohl, J. Stekar (1981)
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.European journal of cancer & clinical oncology, 17 11
-
L. Schuchter, M. Hensley, N. Meropol, E. Winer (2002)
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 12
-
M. Cohen, R. Dagher, D. Griebel, A. Ibrahim, Alison Martin, N. Scher, G. Sokol, Grant Williams, R. Pazdur (2002)
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.The oncologist, 7 5
-
M. Fukuoka, S. Negoro, N. Masuda, K. Furuse, M. Kawahara, N. Kodama, H. Ikegami, S. Nakamura, H. Nishio, T. Ohnoshi (2005)
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disordersJournal of Cancer Research and Clinical Oncology, 117
-
M. Goren, B. Lyman, Jackie Li (1991)
The stability of mesna in beverages and syrup for oral administrationCancer Chemotherapy and Pharmacology, 28
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Springer-Verlag
- Subject
- Medicine
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-004-0801-6
- pmid
- 15184993
- Publisher site
- See Article on Publisher Site
Abstract
The profile of mesna excretion after intravenous and oral dosing in these children was similar to that in reported studies of ifosfamide-treated adults.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Sep 1, 2004